---
title: "updated guidelines for the diagnosis of von willebrand disease SUMMARY OF RECOMMENDATIONS"
slug: "updated-guidelines-for-the-diagnosis-of-von-willebrand-disease-summary-of-recommendations"
date: "2023-09-27"
enableToc: false
tags:
  - building
---

> [!info]
>
> ğŸŒ± ä¾†è‡ª: [[von willebrand disease]]

# updated guidelines for the diagnosis of von willebrand disease SUMMARY OF RECOMMENDATIONS

- For patients with a low probability of VWD, a validated bleeding-assessment tool (BAT) is â†’ recommended as an initial screening tool to identify which patients required specific blood testing over non-standardised clinical assessment.
  - å°æ–¼ VWD å¯èƒ½æ€§ä½çš„ â†’ æ‚£è€…ï¼Œå»ºè­°ä½¿ç”¨ç¶“éé©—è­‰çš„ â†’ å‡ºè¡€è©•ä¼°å·¥å…·  (BAT)  ä½œç‚ºåˆå§‹ç¯©æŸ¥å·¥å…·ï¼Œä»¥ç¢ºå®šå“ªäº›æ‚£è€…éœ€è¦ç‰¹å®šçš„ â†’ è¡€æ¶²æª¢æŸ¥è€Œ âœ– ä¸æ˜¯éæ¨™æº–åŒ–è‡¨åºŠè©•ä¼°ã€‚
- Specific blood testing for VWD refers to VWF antigen (VWF:Ag), platelet-dependent VWF activity (eg, VWF glycoprotein IbM [VWF:GPIbM]), and factor VIII coagulant activity (FVIII:C).
  - VWDçš„ â†’ ç‰¹ç•°æ€§è¡€æ¶²æª¢æ¸¬æ˜¯æŒ‡VWFæŠ—åŸ (VWFï¼šAg) ã€è¡€å°æ¿ä¾è³´æ€§VWFæ´»æ€§ (å¦‚VWFç³–è›‹ç™½IbM [VWFï¼šGPIbM]) å’Œå‡è¡€å› æ•¸VIIIæ´»æ€§ (FVIIIï¼šC) ã€‚
- For patients with an intermediate probability of VWD, BAT should not be relied upon when deciding if a patient requires further specific blood testing.
  - å°æ–¼VWDæ©Ÿç‡ä¸­ç­‰çš„ â†’ æ‚£è€…ï¼Œåœ¨æ±ºå®šæ‚£è€…æ˜¯å¦éœ€è¦é€²ä¸€æ­¥çš„ â†’ ç‰¹ç•°æ€§è¡€æ¶²æª¢æŸ¥æ™‚ï¼Œ âœ– ä¸æ‡‰ä¾è³´BATã€‚
- Intermediate probability is â†’ defined as patients typically presenting with an abnormal bleeding history or abnormal initial laboratory tests.
  - ä¸­ç­‰æ©Ÿç‡å®šç¾©ç‚ºæ‚£è€…é€šå¸¸è¡¨ç¾ç‚ºç•°å¸¸å‡ºè¡€å²æˆ–åˆå§‹å¯¦é©—å®¤æª¢æŸ¥ç•°å¸¸ã€‚
- For patients with a high probability of VWD, BAT should not be relied upon when deciding if a patient requires further specific blood testing.
  - å°æ–¼ VWD å¯èƒ½æ€§é«˜çš„ â†’ æ‚£è€…ï¼Œåœ¨æ±ºå®šæ‚£è€…æ˜¯å¦éœ€è¦é€²ä¸€æ­¥çš„ â†’ ç‰¹ç•°æ€§è¡€æ¶²æª¢æŸ¥æ™‚ï¼Œ âœ– ä¸æ‡‰ä¾è³´ BATã€‚
- High probability patients are typically those with a first-degree relative with VWD, regardless of their bleeding symptoms or initial laboratory results.
  - é«˜æ©Ÿç‡æ‚£è€…é€šå¸¸æ˜¯ä¸€ç´šè¦ªå±¬æ‚£æœ‰ VWD çš„ â†’ æ‚£è€…ï¼Œ âœ– ç„¡è«–å…¶å‡ºè¡€ç™¥ç‹€æˆ–åˆå§‹å¯¦é©—å®¤çµæœå¦‚ä½•ã€‚
- Newer assays, that measure the platelet-binding activity of VWF, for e.g  VWF:GPIbM, VWF:GPIbR, should be used over the VWF ristocetin cofactor assay (VWF:RCo) for the diagnosis of VWD.
  - æ¸¬é‡ VWF è¡€å°æ¿çµåˆæ´»æ€§çš„ â†’ è¼ƒæ–°æª¢æ¸¬æ–¹æ³•ï¼Œä¾‹å¦‚ VWFï¼šGPIbMã€VWFï¼šGPIbRï¼Œæ‡‰ç”¨æ–¼ VWF ç‘æ–¯æ‰˜èŒç´ è¼”å› æ•¸æ¸¬å®š  (VWFï¼šRCo)  ä¾†è¨ºæ–· VWDã€‚
- The diagnosis of patients with type 1 VWD should be reconsidered, rather than removed, if the patientâ€™s VWF levels have normalised with age.
  - å¦‚æœæ‚£è€…çš„ VWF æ°´å¹³éš¨è‘—å¹´é½¡çš„ â†’ å¢é•·è€Œæ¢å¾©æ­£å¸¸ï¼Œå‰‡æ‡‰é‡æ–°è€ƒæ…® 1 å‹ VWD æ‚£è€…çš„ â†’ è¨ºæ–·ï¼Œè€Œ âœ– ä¸æ˜¯å°‡å…¶ç§»é™¤ã€‚
- Aging and comorbidities are known to increase VWF levels, although the association of increased VWF levels and bleeding symptoms, in the setting of a VWD diagnosis is â†’ not established.
  - å·²çŸ¥è¡°è€å’Œåˆä½µç—‡æœƒå¢åŠ  VWF æ°´æº–ï¼Œä½†åœ¨ VWD è¨ºæ–·çš„ â†’ æƒ…æ³ä¸‹ï¼ŒVWF æ°´æº–å‡é«˜èˆ‡å‡ºè¡€ç™¥ç‹€çš„ â†’ é—œè¯å°šæœªç¢ºå®šã€‚
- A VWF levels of <0.30 IU/mL regardless of bleeding symptoms, and a VWF of <0.50 IU/mL with abnormal bleeding, should be used to confirm a diagnosis of type 1 VWD.
  - ç„¡è«–å‡ºè¡€ç™¥ç‹€å¦‚ä½•ï¼ŒVWF æ°´å¹³å‡æ‡‰ç‚º <0.30 IU/mLï¼Œç•°å¸¸å‡ºè¡€æ™‚ VWF æ°´å¹³ç‚º <0.50 IU/mLï¼Œä»¥ç¢ºèª 1 å‹ VWD çš„ â†’ è¨ºæ–·ã€‚
- This refers to VWF levels obtained from VWF:Ag and/or platelet-dependent VWF activity (eg, VWF:GPIbM).
  - é€™æ˜¯æŒ‡å¾VWFï¼šAgå’Œ/æˆ–è¡€å°æ¿ä¾è³´æ€§VWFæ´»æ€§ (å¦‚VWFï¼šGPIbM) ç²å¾—çš„ â†’ VWFæ°´æº–ã€‚
- Furthermore, the lower limit of the normal range defined by the local laboratory should be used, if it is â†’ <0.50 IU/mL.
  - æ­¤å¤–ï¼Œå¦‚æœæ­£å¸¸ç¯„åœçš„ â†’ ä¸‹é™<0.50 IU/mLï¼Œå‰‡æ‡‰ä½¿ç”¨ç•¶åœ°å¯¦é©—å®¤å®šç¾©çš„ â†’ æ­£å¸¸ç¯„åœä¸‹é™ã€‚
- VWF is â†’ a dynamic reactant and diagnostic testing should be performed when the patient is â†’ at â†£ a baseline state of health.
- VWF æ˜¯ä¸€ç¨®å‹•æ…‹åæ‡‰ç‰©ï¼Œæ‡‰åœ¨æ‚£è€…è™•æ–¼åŸºç·šå¥åº·ç‹€æ…‹æ™‚é€²è¡Œè¨ºæ–·æ€§æª¢æŸ¥ã€‚
  - For the diagnosis of type 1C VWD, a trial of desmopressin is â†’ suggested, with 1- and 4-hour post-infusion blood work to confirm increased VWF clearance, as opposed to VWF propeptide (VWFpp)/VWF:Ag testing.
- å°æ–¼ 1C å‹ VWD çš„ â†’ è¨ºæ–·ï¼Œå»ºè­°å˜—è©¦ä½¿ç”¨å»æ°¨åŠ å£“ç´ ï¼Œåœ¨è¼¸æ³¨å¾Œ 1 å°æ™‚å’Œ 4 å°æ™‚é€²è¡Œè¡€æ¶²æª¢æŸ¥ï¼Œä»¥ç¢ºèª VWF æ¸…é™¤ç‡å¢åŠ  â†‘ ï¼Œè€Œ âœ– ä¸æ˜¯ VWF å‰è‚½  (VWFpp) /VWFï¼šAg æª¢æ¸¬ã€‚
  - When type 2 VWD is â†’ suspected, it is â†’ suggested that a platelet-dependent VWF activity/VWF:Ag ratio <0.7 be used as a cut-off, rather than <0.5, for patients with an abnormal initial VWD screen.
- ç•¶æ‡·ç–‘ 2 å‹ VWD æ™‚ï¼Œå»ºè­°å°‡è¡€å°æ¿ä¾è³´æ€§ VWF æ´»æ€§/VWFï¼šAg æ¯”å€¼ <0.7 ä½œç‚ºè‡¨ç•Œå€¼ï¼Œè€Œ âœ– ä¸æ˜¯ <0.5ï¼Œç”¨æ–¼åˆå§‹ VWD ç¯©æŸ¥ç•°å¸¸çš„ â†’ æ‚£è€…ã€‚
- This is â†’ because some type 2 VWD patients can have a normal VWF:Ag and platelet-dependent VWF activity but a low ratio of platelet-dependent VWF activity/VWF:Ag.
  - é€™æ˜¯ âˆµ å› ç‚ºä¸€äº› 2 å‹ VWD æ‚£è€…çš„ VWFï¼šAg å’Œè¡€å°æ¿ä¾è³´æ€§ VWF æ´»æ€§æ­£å¸¸ï¼Œä½†è¡€å°æ¿ä¾è³´æ€§ VWF æ´»æ€§/VWFï¼šAg çš„ â†’ æ¯”ç‡è¼ƒä½ã€‚
- It is â†’ also suggested that if additional testing is â†’ required for the diagnosis of type 2A, 2B or 2M VWD, that VWF multimer analysis or VWF collagen binding (VWF:CB)/VWF:Ag (the ratio of VWF collagen binding to antigen) be used.
  - é‚„å»ºè­°ï¼Œå¦‚æœéœ€è¦å° 2Aã€2B æˆ– 2M å‹ VWD çš„ â†’ è¨ºæ–·é€²è¡Œé¡å¤–çš„ â†’ æª¢æŸ¥ï¼Œå‰‡ä½¿ç”¨ VWF å¤šèšé«”åˆ†ææˆ– VWF è† åŸçµåˆ  (VWFï¼šCB) /VWFï¼šAG (VWF è† åŸèˆ‡æŠ—åŸçµåˆçš„ â†’ æ¯”ç‡) ã€‚
- If additional testing is â†’ required for the diagnosis of type 2A or 2B VWD, targeted genetic testing is â†’ suggested over low-dose ristocetin-induced platelet agglutination (RIPA) (Figure 2).
  - å¦‚æœéœ€è¦é¡å¤–çš„ â†’ æª¢æ¸¬ä¾†è¨ºæ–·2Aå‹æˆ–2Bå‹VWDï¼Œå»ºè­°é€²è¡Œé¶å‘åŸºå› æª¢æ¸¬ï¼Œè€Œ âœ– ä¸æ˜¯ä½åŠ‘é‡ç‘æ–¯æ‰˜èŒç´ èª˜å°çš„ â†’ è¡€å°æ¿å‡é›† (RIPA)  (åœ–2) ã€‚
- Finally, it is â†’ suggested to use either VWF FVIII binding (VWF:FVIIIB) or targeted genetic testing for the diagnosis of type 2N VWD that requires additional testing (Figure 3).
  - æœ€å¾Œï¼Œå»ºè­°ä½¿ç”¨VWF FVIIIçµåˆ (VWFï¼šFVIIIB) æˆ–é¶å‘åŸºå› æª¢æ¸¬ä¾†è¨ºæ–·éœ€è¦é¡å¤–æª¢æ¸¬çš„ â†’ 2N VWDå‹ (åœ–3) ã€‚
